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Abstract: In recent years, bacterial infections have become a main concern following the spread
of antimicrobial resistance. In addition, bacterial biofilms are known for their high tolerance to
antimicrobials and they are regarded as a main cause of recalcitrant infections in humans. Many efforts
have been deployed in order to find new antibacterial therapeutic options and the high-throughput
screening (HTS) of large libraries of compounds is one of the utilized strategies. However, HTS efforts
for anti-biofilm discovery remain uncommon. Here, we miniaturized a 96-well plate (96WP)
screening platform, into a 384-well plate (384WP) format, based on a sequential viability and biomass
measurements for the assessment of anti-biofilm activity. During the assay optimization process,
different parameters were evaluated while using Staphylococcus aureus and Pseudomonas aeruginosa
as the bacterial models. We compared the performance of the optimized 384WP platform to our
previously established 96WP-based platform by carrying out a pilot screening of 100 compounds,
followed by the screening of a library of 2000 compounds to identify new repurposed anti-biofilm
agents. Our results show that the optimized 384WP platform is well-suited for screening purposes,
allowing for the rapid screening of a higher number of compounds in a run in a reliable manner.
Keywords: bacteria; biofilms; crystal violet; resazurin; screening; Staphylococcus aureus;
Pseudomonas aeruginosa
1. Introduction
Biofilms are multicellular communities of bacteria that are attached to a surface and embedded in a
self-produced polymeric matrix that provide them with protection in various environments, including
in the human body. Biofilms are well known for their greater tolerance, not only to the host immune
system, but also to antimicrobials; they can withstand 10- to 1000-fold higher concentrations than
cells in planktonic form [1–3]. These features make biofilms very difficult to treat and, as a result,
they are responsible for the majority of recalcitrant infections, often leading to chronic infections and
resulting in a high cost to the healthcare system as well as significant morbidity and mortality [3–6].
Antibiotic treatments can eliminate planktonic cells, but they fail to eradicate biofilms. This has been
attributed to a combination of many mechanisms, including the physical protection given by the biofilm
matrix, heterogeneity in the metabolic activity of the cells residing within the biofilm, and specific
gene expression changes leading to a biofilm-specific phenotype [3,7,8]. In many cases, the only
possible treatment of a persistent biofilm infection is to surgically remove the biofilm. In the case of
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medical device-related infections, the removal and replacement of the implant is often needed [9].
In addition to a biofilm’s intrinsic tolerance to antimicrobials, the development of antibiotic resistance
is also a major problem, as increasing amounts of pathogens are multi-resistant to the currently used
antibiotics [10,11]. For all of these reasons, finding new therapeutic options that are effective against
biofilms is crucial, and intensive research is now ongoing for discovering new antimicrobials [12].
One approach for tackling this challenge is conducting high-throughput screening (HTS) of
compound libraries using assays that test the antimicrobial activity of compounds on biofilms grown in
96-well plates (WP) [13,14]. This approach is very commonly used in early drug discovery, as it allows
the rapid testing of a large number of compounds in a single run, using very small amount of the tested
compounds [4,15–17]. The scientific community has extensively used microplates to grow bacterial
biofilm [13,18–23], and it has been the preferred sample format used by our group in several studies.
For instance, our previous efforts led to the optimization of a phased-screening platform in 96WP,
which allowed for monitoring the anti-biofilm activity against Staphylococcus aureus by measuring the
viability, biomass, and the biofilm matrix [14,15,24]. A primary screening for effects on viable cells and
biofilm biomass was conceived, so that two assays could be sequentially performed in a single plate,
in order to reduce the time and the amount of materials and compounds required for the analysis.
A follow-up assay, involving the fluorescence staining of the poly-β-1,6-N-acetyl-D-glucosamine
(PNAG) component, was further optimized for measuring the specific effects of active compounds on
the biofilms matrix of S. aureus [24].
For the initial screening analysis, assays that were based on resazurin and crystal violet staining
were first optimized to measure the viability and biofilm biomass of S. aureus, respectively. Resazurin is
a blue non-fluorescent dye that is only reduced in metabolically active cells into resorufin, a pink
fluorescent product that can then be measured. The resazurin staining assay is widely used to
evaluate the viability of bacterial cells, as it is fast, shows good repeatability, and has the advantage of
discriminating live and dead cells [13]. However, it requires high cell density and living but non-growing
cells within biofilms cannot be detected by this method [15]. On the other hand, crystal violet is a widely
used basic purple dye that stains negatively charged surfaces (e.g., cell membranes and polysaccharides
in the biofilm matrix) [25]. It does not differentiate live from dead cells, but it measures a biofilm’s
overall biomass, which makes it a useful complementary assay to resazurin staining [24]. Despite the
benefits of these staining methods, screening larger libraries using the 96WP-based platform is still
labor-intensive and it requires a significant quantity of the tested compounds.
In view of this, we miniaturized both the resazurin and crystal violet assays for microtiter plates
with 384 wells (384WP) to test the applicability of this platform to screen larger number of compounds
within a same plate in a shorter time and requiring less reagents per well. The optimization was
performed with S. aureus ATCC 25,923 and Pseudomonas aeruginosa ATCC 15442, two representative
model organisms for gram-positive and gram-negative bacteria, respectively. Parameters, such as the
working volume, the concentration of the bacterial inoculum (CFU mL−1), as well as the resazurin and
crystal violet staining conditions, were optimized. Throughout the optimization process, the screening
window coefficient known as the Z’ factor (Z’), a statistical parameter monitoring the reliability of
the screening assay and assay performance, was measured. The signal-to-noise (S/N) ratio was also
monitored. The inhibition of biofilm formation by well-known antibiotics was compared in both 384WP
and 96WP to validate the miniaturized model. A proof-of-concept pilot screen of 100 compounds was
also performed against S. aureus biofilms in both platforms in order to evaluate the correlation of results
between 384WP and 96WP. Based upon these results, a screening campaign against S. aureus biofilms
was performed while using a library of 2000 structurally diverse compounds, including approved drugs,
natural products, as well as biologically relevant compounds that have been reported in peer-reviewed
publications. The main goal here was to identify repurposed anti-biofilm compounds because this
library was composed by approximately 60% of FDA-approved or internationally marketed drugs.
Different methods for quantifying the effect of antibacterial compounds have earlier been
miniaturized for 384WP, but such efforts have been particularly uncommon for anti-biofilm
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screening. For example, an optical density (OD)-based minimum inhibitory concentration (MIC)
assay has been used with S. aureus and P. aeruginosa; however, it does not allow for biofilm
quantification [26,27]. Redox-based assays, such as those based on resazurin, have been optimized
in 384WP format for various bacterial species, including Klebsiella pneumoniae, Helicobacter pylori,
Streptococcus pneumoniae, Neisseria species, P. aeruginosa, and S. aureus, but these analyses have only
involved planktonic cells [28–32]. A combination of an image-based method and the redox-based
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay to measure the
inhibition of P. aeruginosa biofilm formation and dispersion has been developed in 384WP [33].
However, this platform is based on more expensive instrumentation, and it requires the use of a mutant
GFP (green fluorescent protein)-tagged bacterial strain, which limits the application of this assay for
studying different bacterial strains and species.
By contrast, the 384WP anti-biofilm screening platform that has been miniaturized here involves a
cost-friendly combination of sequential staining with resazurin and crystal violet, which can be applied
to different bacterial strains and species. For cases where assays conditions that are described here
are not directly applicable, all of the optimization steps are described in detail and can be used as
guidance. Moreover, both of the assays are fast, easy-to-use and amenable to automation. Thus far,
the resazurin assay has been optimized in 384WP for anti-biofilm activity assessment on fungi [34].
In one contribution [35], a combined resazurin and crystal violet-based platform has been used for
anti-biofilm screening while using Staphylococcus epidermidis. However, the optimization process was
not reported, and a comparative performance study between the 384WP and the conventional 96WP
platform was not carried out, either. Our experiments demonstrate that the 384WP format can be
successfully used for fluorescence- and absorbance-based anti-biofilm HTS with large compound
libraries. As demonstrated here, 384WP provide reliable as well as reproducible screening results that
are comparable to the 96WP-based platform. To the best of our knowledge, this is the first validation
of a platform combining both resazurin and crystal violet staining assays in 384WP on S. aureus
and P. aeruginosa. Our optimization efforts were culminated by a screening campaign that involved
2000 compounds, where 77 hits were identified, for a 3.8% success rate.
2. Results and Discussion
2.1. Optimizing the Working Volume and Initial Bacterial Concentration for 384WP
When optimizing assays that were aimed at screening a large number of compounds, it is important
that these assays are simple to execute, cost-friendly, rapid, and that they require low amounts of
materials. These are features shared by both the resazurin and crystal violet staining assays. Since
multiple replicates of tested compounds are not typically included, the assays must perform robustly
and consistently. To that end, the screening assays must be carefully optimized, and their performance
needs to be rigorously monitored, also, throughout screening campaigns, using appropriate screening
parameters, such as the screening window coefficient - Z’, which was originally published by [36].
The screening method was optimized in terms of the assay time and the amount of material
needed, and the quality of the method was validated by calculating the Z’ factor (Z’). We first optimized
the bacterial concentration and working volume for the 384WP-based platform. For these initial
experiments, the resazurin and crystal violet assays were performed while using the conditions that
were previously described by our group [24]. Five starting concentrations of planktonic bacteria,
including the cell concentration routinely used in 96WP for S. aureus, were tested. The first of the
concentrations was the same as the one used previously in 96WP and the second concentration was
proportionally reduced from the first concentration to match the smaller growth area at the bottom of
the 384WP and reach a similar initial concentration per surface (CFU cm−2) concentration. The tested
concentrations for S. aureus were 4.00 × 106 CFU ml−1, 7.00 × 105 CFU mL−1, 2.50 × 106 CFU mL−1,
7.00 × 104 CFU mL−1, and 7.00 × 103 CFU mL−1. In the case of P. aeruginosa, the following five
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cell concentrations were tested: 1.00 × 107 CFU mL−1, 6.25 × 106 CFU mL−1, 1.75 × 106 CFU mL−1,
1.75 × 105 CFU mL−1, and 1.75 × 104 CFU mL−1.
Each bacterial concentration was tested in 384WP while using two different working volumes (that
is, total volume in the wells, 40 µL and 50 µL) and two different growth periods (18 h that is routinely
used in pre-exposure experiments in 96WP and 42 h that is used in post-exposure experiments in
96WP). For evaluating the assay performance, the Z’ factor was calculated and then compared between
each condition. The Z’ evaluates the separation between the maximal signal and the background
signal of an assay and it is the most appropriate and widely used statistical parameter to assess the
performance of a screening method [36,37]. It ranges between 0 and 1. A value of 0 signifies no
distinction between the maximal and minimal signal, whereas a value of 1 indicates that the signal
separation is ideal and infinite (an ideal screening assay). Consequently, a Z’ value that is close to
0 indicates that the assay does not perform well and it requires more optimization. Generally, a Z’
value above 0.5 indicates a well-performing assay, although, in the case of cell-based assays, a Z’ above
0.35 is already considered to be acceptable [38]. The difference between the maximal and minimal
signals obtained in each condition was also compared. Parameters that resulted in the best Z’ factor
were selected as being optimal. The correlation between the Z’ factor and the signal-to-noise ratio
(S/N), as defined by [36], obtained for both assays, during the optimization stage, was also monitored
(Supplementary Figure S1a). The two statistical parameters showed a consistent correlation, where a
good Z’ value (above 0.5) generally equaled an S/N above six.
When testing the platform with S. aureus using both the resazurin and crystal violet on 18 h-old or
42 h-old biofilms (Figure 1), the two different working volumes (40 and 50 µL) did not significantly
affect the Z’ values (p ≥ 0.05) or the maximum minus the minimum signals. With a working volume as
low as 40 µL, it was possible to obtain high quality data and this working volume was therefore selected
for further experiments. A lower working volume (25 µL) was also tested, but the wells fully dried out
during incubation, so we concluded that so small working volumes in 384WP assays involving longer
incubation times would not be feasible due to evaporation issues. The initial S. aureus concentration did
not significantly impact the Z’ values regarding the resazurin assay; the majority of the tested S. aureus
concentrations reached a biofilm state with similar metabolic activity after 18 or 42 h of incubation.
The 7.00 × 104 CFU mL−1 was the lowest cell concentration, resulting in a good Z’ value (≥ 0.5) for
both the young (18 h) and more mature (42 h) biofilms. A slightly increased difference between the
maximal and minimal signals was observed with increased S. aureus concentrations, even though it
did not translate into a higher Z’ value.
The crystal violet assay was more influenced by the initial S. aureus concentrations, and a lower cell
concentration was usually related to a lower Z’ value and a smaller difference between the maximum
and minimum signals. This staining method generally resulted in a lower performance than resazurin;
it requires more steps that can introduce variability and is more laborious, which translates into a lower
reproducibility and a poorer dynamic range [39]. For this assay, all of the cell concentrations from
2.50 × 106 CFU mL−1 and higher still resulted in a good Z’ value (≥ 0.5). As our findings indicated that
the resazurin staining produces more reliable results than the crystal violet staining, and since both
assays are performed sequentially in the same plate, the initial bacterial concentration that was selected
for the subsequent assays was the compromise of both staining methods (7.00 × 104 CFU mL−1),
which performed well with the resazurin staining while still giving an acceptable performance with
crystal violet.
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of S. aureus biofilms grown for 18 h or 42 h in a volume of 40 µL or 50 µL with different initial bacterial 
concentration in 384WP. Maximum minus minimum results are expressed in relative fluorescence 
units (RFUs) for resazurin or relative absorbance units (RAUs) for crystal violet. The results are based 
on 2–4 independent biological replica experiments, each plate containing 28–40 technical replicates 
for each condition and 30 media control replicates. The red lines in panels a and b represent the 
thresholds for determination of the quality of the assay: acceptable (Z = 0.35) and good (Z = 0.5). 
The optimized screening platform was also tested with gram-negative P. aeruginosa biofilms 
(Figure 2). With this strain, neither the volume nor the initial bacterial concentration affected the Z’ 
values for both staining assays (p ≥ 0.05). The resazurin assay signals varied significantly, but the 
position of the biofilm controls (maximal signal) within the plate affected more strongly the metabolic 
activity of the biofilms than the initial quantity of bacteria. Wells on the edges of the plate showed 
more varying results, which was also found between different replica plates. While this effect is well 
known in 96WP, it was particularly noticeable in 384WP, probably because of the smaller size of the 
wells and smaller working volumes. The resazurin assay did not perform as well with P. aeruginosa 
as it did with S. aureus and it rarely resulted in Z’ values above 0.35, indicating the need for optimizing 
other assay parameters or more accurate optimization of the tested parameters for this gram-negative 
model. As the conditions for this assay were not fully optimized, these observations were considered 
to be normal at this point. The crystal violet staining results did not vary much with respect to the 
working volume or the initial cell concentration. For further experiments, a bacterial concentration of 
1.75 × 105 CFU mL−1 was selected, as it resulted in lower intra-plate variability when using resazurin 
as the staining method. For the next part of the optimization, different parameters of the resazurin 
and crystal violet staining methods were adjusted in order to select the best conditions for both 
bacterial species. 
Figure 1. Effect of different initial S. aureus concentrations and working volumes on the performance of
a miniaturized biofilm screening assay in 384WP. Assay performance is measured using the Z’ factor
(a,b) and the maximum minus minimum signal (c,d) of the resazurin and crystal violet staining of
S. aureus biofilms grown for 18 h or 42 h in a volume of 40 µL or 50 µL with different initial bacterial
concentration in 384WP. Maximum minus minimum results are expressed in relative fluorescence units
(RFUs) for resazurin or relative absorbance units (RAUs) for crystal violet. The results are based on 2–4
independent biological replica experiments, each plate containing 28–40 technical replicates for each
condition and 30 media control replicates. The red lines in panels a and b represent the thresholds for
determination of the quality of the assay: acceptable (Z = 0.35) and good (Z = 0.5).
The optimized screening platform was also tested with gram-negative P. aeruginosa biofilms
(Figure 2). With this strain, neither the volume nor the initial bacterial concentration affected the
Z’ values for both staining assays (p ≥ 0.05). The resazurin assay signals varied significantly, but the
position of the biofilm controls (maximal signal) within the plate affected more strongly the metabolic
activity of the biofilms than the initial quantity of bacteria. Wells on the edges of the plate showed
more varying results, which was also found between different replica plates. While this effect is well
known in 96WP, it was particularly noticeable in 384WP, probably because of the smaller size of the
wells and smaller working volumes. The resazurin assay did not perform as well with P. aeruginosa as
it did with S. aureus and it rarely resulted in Z’ values above 0.35, indicating the need for optimizing
other assay parameters or more accurate optimization of the tested parameters for this gram-negative
model. As the conditions for this assay were not fully optimized, these observations were considered
to be normal at this point. The crystal violet staining results did not vary much with respect to the
working volume or the initial cell concentration. For further experiments, a bacterial concentration of
1.75 × 105 CFU mL−1 was selected, as it resulted in lower intra-plate variability when using resazurin
as the staining method. For the next part of the optimization, different parameters of the resazurin
and crystal violet staining methods were adjusted in order to select the best conditions for both
bacterial species.
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violet staining of P. aeruginosa biofilms grown for 18 h or 42 h in a volume of 40 µL or 50 µL with 
different initial bacterial concentration in 384WP. Maximum minus minimum results are expressed 
in RFUs for resazurin or RAUs for crystal violet. Results are based on 3–4 independent biological 
replica experiments, each plate containing 28–40 technical replicates for each condition and 30 media 
control replicates. The red lines in panels a and b represent the thresholds for the determination of 
the quality of the assay: acceptable (Z = 0.35) and good (Z = 0.5). 
2.2. Optimizing the Conditions for Resazurin Staining 
Our pre-existing screening platform developed in-house [24] is based on staining the biofilms 
first with resazurin and then by crystal violet in the same 96WP. Using both assays has the advantage 
of giving more information of the activity of an antibacterial compound and its mechanism of action 
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Figure 2. The effect of different initial P. aeruginosa concentrations and working volumes on the
performance of a miniaturized biofilm screening assay in 384WP. Assay performance is measured
using the Z’ factor (a,b) and the maximum minus minimum signal (c,d) of the resazurin and crystal
violet staining of P. aeruginosa biofilms grown for 18 h or 42 h in a volume of 40 µL or 50 µL with
different initial bacterial concentration in 384WP. Maximum minus minimum results are expressed in
RFUs for resazurin or RAUs for crystal violet. Results are based on 3–4 independent biological replica
experiments, each plate containing 28–40 technical replicates for each condition and 30 media control
replicates. The red lines in panels a and b represent the thresholds for the determination of the quality
of the assay: acceptable (Z = 0.35) and good (Z = 0.5).
2.2. Optimizing the Conditions for Resazurin Staining
Our pre-existing screening platform developed in-house [24] is based on staining the biofilms
first with resazurin and th n by crys al violet in the same 96WP. Using oth assays has the advantage
of giving more informatio of the ctivity of an antibacterial compound and its mechanism of
action (MoA) and doing it in a single plate allows for correlating the results of e ch assay to a
single biofilm. When evaluating he anti-bi film pote tial of a compound, it is important to make
a distinction between the compounds that eliminate living cells (i.e., revent resazurin reduction),
and those that preve t biofilm formation/disrupt th biofilm (i. ., reduce crystal violet staining).
Analyzing the ef ects of the com ounds n biof lms using both staining methods is of particular
importance, because, if only living ce ls are elimina ed, the remaining biofilm mat ix becomes an ideal
environment for a quick recolonization, leading to a r currence of the n ection [18,40]. The non-i vasive
nature of resazurin [24,41] allows for the subs quent perfo manc of addi ional staini g assays within the
same plate, which minimizes the plate-to-plate variations when using multiple staining methods duri g
the screen ng proce s. The correlation between the Z’ factor and the S/N obtai ed for the optimiza on
of the conditions of both the r sazuri and c ystal violet assays was monitored (Supplement ry Material
Figure S1b). Similar to the optimization f working volume and bacteria co centration, there was a cle r
correlation between the Z’ and the S/N and a good Z’ value (above 0.5) translated into an S/N above 6.
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The resazurin assay measures the metabolic activity of the cells, which can greatly vary between
different strains, indicating that the method has to be optimized for each tested species or strain [24,42].
Here, the resazurin staining conditions were optimized using 40 µL as the working volume with an
initial cell concentration of 7.00 × 104 CFU mL−1 for S. aureus and 1.75 × 105 CFU mL−1 for P. aeruginosa.
Different resazurin concentrations within the range of 20 µM to 200 µM were tested and fluorescence
was measured at different time points (from 5 to 80 min.).
With the S. aureus 18 h-old biofilms, the Z’ values that were obtained while testing the various
concentrations of resazurin (20–100 µM) were consistently above 0.35 after 10 min. of incubation
and above 0.5 after 30 min. (Figure 3a). With resazurin at 20 µM, a concentration routinely used in
96WP, the assay performance was overall better when compared to higher resazurin concentrations.
In addition, only a minimum of 10 min. of incubation was needed to reach a Z’ above 0.5. With 42 h-old
biofilms, resazurin at 40µM was slightly more optimal and an incubation of at least 30 min. was required
to reach a Z’ above 0.5 (Figure 3b), but only a marginal benefit was obtained with a longer incubation
time. In general, the longer the incubation was, the better the Z’ factor and the wider the separation
between the maximum and minimum signals (Figure 3c,d). On the other hand, while the difference
between the maximum and minimum signals significantly increased over time, the increase of the
Z’ factor slowed down quickly. Therefore, for further experiments, resazurin at the concentration of
20 µM was selected to test 18 h-old S. aureus biofilms and 40 µM for 42 h-old biofilms using 30 min.
incubation for each.
As expected, different conditions were required for the staining of P. aeruginosa, thus confirming
the need for species-dependent optimization (Figure 4). With both 18 h-old or 42 h-old biofilms,
regardless of the concentration of resazurin used, a Z’ above 0.5 could never be reached and only
the longest incubation times would allow for reaching a Z’ of at least 0.3. Despite the higher initial
cell concentration used, P. aeruginosa produced a much lower fluorescence signal than S. aureus.
The possible explanations include strain-specific differences affecting the reduction rate of resazurin or
a greater thickness or sliminess of P. aeruginosa biofilms hampering the penetration of resazurin [42].
Therefore, P. aeruginosa biofilms were stained at 37 ◦C, which significantly increased the Z’ factor,
in order to increase the metabolic activity and improve the sensitivity of the resazurin assay. With long
incubation times (60–80 min.), all of the tested resazurin concentrations provided acceptable (Z’ > 0.35)
to good (Z’ > 0.5) performance values with 18 h-old P. aeruginosa biofilms (Figure 4a). The resazurin
concentration of 100 µM resulted in the best Z’ factor with both the 18 h and 42 h-old biofilms
(Figure 4a,c). An incubation of at least 60 min. with 18 h-old biofilms and 80 min. with 42 h-old
biofilms was necessary to ensure proper assay performance. Of note, performing the assay at 37 ◦C also
increases the fluorescence signal obtained from the S. aureus biofilms, but further resazurin staining
assays with S. aureus were still performed at RT, as carrying out the assay at RT was enough to obtain
good assay performance.
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Figure 3. Effect of different resazurin concentrations and incubation times with the dye on the
performance of a miniaturized biofilm screening assay in 384WP with S. aureus. Assay performance is
measured using Z’ factor (a,c) and maximum minus minimum signal (b,d) of the resazurin staining
of S. aureus biofilms grown for 18 h or 42 h in a volume of 40 µL with a concentration of the bacterial
inoculum of 7.00 × 104 (CFU) mL−1. (e,f) show the Z’ factor and the maximum minus minimum signal
obtained with the best resazurin concentration over time. Maximum minus minimum results are
expressed in RFUs. Results are based on 2–4 independent biological replica experiments performed at
room temperature (RT), each plate containing from 12 to 42 technical replicates and 16 media control
replicates for each condition. The red lines in panels a, c and e represent the thresholds for determination
of the quality of the assay: acceptable (Z’ = 0.35) and good (Z’ = 0.5).
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for the bound crystal violet. Additionally, different incubation times with the dye (5, 10, and 15 min.) 
Figure 4. Effect of different resazurin concentrations and incubation times with the dye on the
performance of a miniaturized biofilm screening assay in 384WP with P. aeruginosa. Assay performance
is measured using Z’ factor (a,c) and maximum minus minimum signal (b,d) of the resazurin staining
of P. aeruginosa biofilms grown for 18 h or 42 h in a volume of 40 µL with a concentration of the bacterial
inoculum of 1.75 × 105 CFU mL−1. (e,f) show the Z’ factor and the maximum minus minimum signal
obtained with the best resazurin concentration over time. Maximum minus minimum results are
expressed in RFUs. Results are based on 2 independent biological replica experiments performed at
37 ◦C, each plate containing from 36 to 48 technical replicates and 12 media control replicates for each
condition. The red lines in panels a, c, and e represent the thresholds for determination of the quality of
the assay: acceptable (Z’ = 0.35) and good (Z’ = 5).
2.3. Optimizing the Conditions for Crystal Violet Staining
The crystal violet staining was performed on the same biofilms that were used for the resazurin
staining. Different concentrations of crystal violet and lengths of incubation times were tested
with both bacterial species. In the case of S. aureus, the absorbance of the stained biomass was
also measured at different time points after the addition of ethanol to dissolve the bound crystal
violet. The Z’ factor increased proportionally to the dissolution time for one hour and then stabilized
(Supplementary Figure S2b). An hour was consequently selected as the most optimal dissolution time
for the bound crystal violet. Additionally, different incubation times with the dye (5, 10, and 15 min.)
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did not significantly affect the assay performance (Supplementary Figure S2a); therefore, the shortest
time (5 min.) was selected for further assays. While the crystal violet assay more variable results than
resazurin [42], statistically acceptable results could still be obtained in our study.
With S. aureus biofilms (Figure 5a,c) the crystal violet at 0.023% (v/v) provided higher Z’ values,
although the difference between the maximum and minimum signal was greater with higher crystal
violet concentrations. The most likely reason for this could be the reduced inter-well variability detected
with lower crystal violet concentrations, since using higher concentrations of crystal violet occasionally
led to darkly stained media control wells containing no bacteria. With P. aeruginosa (Figure 5b,d),
the three lowest concentrations of crystal violet resulted in very similar Z’ factors and maximum minus
minimum values, especially on 42 h-old biofilms. The crystal violet concentration of 0.1% (v/v) gave an
average Z’ value above 0.5 with both young and older P. aeruginosa biofilms.
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Next, we compared the number of viable cells attached as biofilms in 384WP versus 96WP. The 
S. aureus and P. aeruginosa biofilms that were produced in each plate were scraped, serially diluted, 
and plated on tryptic soy agar (TSA). Viable colonies (CFUs) were counted the next day and the 
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Figure 5. Effect of different crystal violet concentrations on the performance of a miniaturized biofilm
screening assay in 384WP. Assay performance is measured using Z’ factor (a,b) and maximum minus
minimum signal (c,d) of the crystal violet staining of S. aureus and P. aeruginosa biofilms grown for 18 h
or 42 h in a volume of 40 µL with a concentration of the bacterial inoculum of 7.00 × 104 CFU mL−1
(S. aureus) or 1.75 × 105 CFU mL−1 (P. aeruginosa). Maximum minus minimum results are expressed in
RAUs. Results are based on 3–5 independent biological replica experiments, with each plate containing
from eight (one experiment) to 96 technical replicates and 12 to 32 media control replicates for each
condition. The red lines in panels a and b represent the thresholds for determination of the quality of
the assay: acceptable (Z = 0.35) and good (Z = 5).
2.4. Biofilm Formation in 384WP in Comparison with 96WP
Next, we compared the number of viable cells attached as biofilms in 384WP versus 96WP.
The S. aureus and P. aeruginosa biofilms that were produced in e ch plate were scraped, serially diluted,
and plated on tryptic soy agar (TSA). Viable colonies (CFUs) were counted th next day and the amount
of CFUs in each biofilm was normalized to the area (cm2) of the wells i both syst ms (Figure 6).
With S. aureus, a similar amount of CFU cm−2 was obs rved betwe n the 18 h-old and 42 h-old
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biofilms, as well as in the 96WP and 384WP plates, suggesting a similar cell density. On the other
hand, with P. aeruginosa, the number of CFU cm−2 was slightly reduced by 0.6–0.8 log in 384WP when
compared to 96WP. It could be that biofilms that formed by P. aeruginosa were less dense or had a
different structure in the smaller wells of 384WP, which stimulated cell dispersal. However, overall,
a relatively similar cell density was still achieved in biofilms that were grown for 18 h and 42 h in each
plate model. It is possible that, in the restricted space of the wells, biofilms reached a maximal number
of cells within the given area or that the time span between the two time points studied was not long
enough to result in a detectable cell density difference. In any case, the differences between responses
in 18 h versus 42 h biofilms cannot be attributed to a larger number of viable cells attached on the wells,
at least on our assay conditions.
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Figure 6. Log10 of the CFUs per cm2 of S. aureus (black) and P. aeruginosa (striped) biofilms grown in
96WP or 384WP for 18 h or 42 h. The data represents the average of 16–22 biofilms (technical replicates)
from 2–5 independent biological replica experiments.
2.5. Susceptibility of S. aureus Biofilms Formed in 384WP and 96WP to Antibiotics
We further evaluated the susceptibility of S. aureus biofilms to a panel of standard antibiotics at
seven different concentrations (10 µM to 0.01 pM) while using the pre- and post-exposure modes in
order to compare the screening results obtained between the miniaturized 384WP platform and the
characterized 96WP platform (Figure 7). Overall, the susceptibility of the biofilms was comparable
in both models, which confirms the applicability of the 384WP model for antibacterial activity
assessment. The biofilm viability inhibition percentages that were obtained with the resazurin assay
in the pre-exposure mode were very similar between the 96WP and the 384WP, with an average
difference of inhibition percentage under 6 % (5.5% ± 5.8%). When using the post-exposure mode,
the difference between the viability inhibition results that were obtained in 96WP and in 384WP
increased, with an average difference of inhibition of almost 15% (14.3% ± 7.7%). With the crystal violet
assay, an average difference of biomass formation inhibition of 11.4% ± 8.9% was observed between
96WP and 384WP in pre-exposure and 10.6% ± 7.5% in post-exposure. Thus, performing the assays in
384WP rather than in 96WP produced a very similar outcome and did not result in generally higher
or lower inhibition values at the different concentrations of antibiotics tested. Still, it is important to
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note that, in our experiments, with both species, the initial bacterial concentration was about 70 times
lower in 384WP than in 96WP, which could have affected the antimicrobial susceptibility during the
early stages of bacterial growth prior to biofilm formation and especially in pre-exposure experiments.
Some compounds that have a rapid MoA on bacteria might perform differently in both models when
using the same assay conditions that are described here.
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96WP and 384WP is available in the Supplementary Materials (Table S1). Similar to previous findings, 
the majority of the results correlated between 384WP and 96WP, but a slight difference was observed; 
the inhibition values that were obtained using post-exposure mode in 384WP were generally higher 
than values obtained in 96WP (by 18% with resazurin and 11% with crystal violet). This difference 
was not observed with the pre-exposure mode and it would be unlikely to cause major differences in 
the conclusions of a screening, since screenings in the early discovery of antibacterial compounds 
typically evaluate the prevention of growth (pre-exposure) rather than the antimicrobial effects on 
Figure 7. Correlation of the susceptibility of S. aureus biofilms to different concentrations of four
antibiotics (rifampicin, oxacillin, doxycycline, penicillin G) in 96WP and 384WP in pre- (a,c) and
post-exposure (b,d) modes. The effect of the antibiotics on the biofilms was assessed by resazurin
(“Viability”, (a,b)) and crystal violet (“Total Biomass”, (c,d)) staining. Results are expressed as inhibition
percentages of viability or biomass in comparison to untreated biofilms and they are based on two
independent biological replica experiments, with two (96WP) or eight (384WP) technical replicates for
each condition.
2.6. Antibacterial Pilot Screening Against S. aureus Biofilms in 384WP and 96WP Platforms
We performed a pilot screen of 100 compounds, which included natural derivatives as well as
10 antibiotics, at 10 µM, to further verify the applicability of 384WP for antibacterial screening in a
larger scale (Figure 8). The list of all of the tested compounds, sources, and their screening results in
96WP and 384WP is available in the Supplementary Materials (Table S1). Similar to previous findings,
the majority of the results correlated between 384WP and 96WP, but a slight difference was observed;
the inhibition values that were obtained using post-exposure mode in 384WP were generally higher
than values obtained in 96WP (by 18% with resazurin and 11% with crystal violet). This difference
was not observed with the pre-exposure mode and it would be unlikely to cause major differences
Int. J. Mol. Sci. 2020, 21, 3034 13 of 24
in the conclusions of a screening, since screenings in the early discovery of antibacterial compounds
typically evaluate the prevention of growth (pre-exposure) rather than the antimicrobial effects on
pre-existing biofilms (post-exposure). It is still a difference that must be taken in consideration for
post-exposure screenings.
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Figure 8. Inhibition of S. aureus biofilms by 100 compounds tested at 10 µM in 96WP and 384WP in
pre (a,c) and post-exposure (b,d) modes. The effect of the compounds on the biofilms was assessed by
resazurin (“Viability, (a,b)) and crystal violet (“Total biomass”, (c,d)) staining. Results are expressed
as inhibition percentages of viability or biomass in comparison to untreated biofilms and they are
based on two independent biological replica experiments, with one (96WP) or two (384WP) technical
replicates for each condition.
In the pre-exposure mode, one of the antibiotics (streptomycin) resulted in significantly different
inhibition values in 384WP and 96WP. An inhibition of 100% with streptomycin was observed in 384WP,
while this antibiotic only inhibited 30 to 40% of the biofilm formation in 96WP. Such a phenomenon was
exclusively seen with streptomycin. It is plausible that the lower concentration of the bacterial cells in
384WP in the beginning of the experiment affected the outcome of the assay. However, this difference
between 384WP and 96WP was not observed when using the post-exposure mode for this antibiotic.
This can be explained by the fact that, after 18 h (when the treatment with streptomycin starts in the
post-exposure assay), the number of viable cells attached is very similar between 384WP and 96WP
(Figure 6), making comparable effects of streptomycin in both systems. Overall, the average difference
in the resazurin and crystal violet staining results between 384WP and 96WP for the same compounds
was 8.7% ± 9.3% in pre-exposure and 15.6% ± 10.5% in post-exposure. Therefore, the results that
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were obtained in both plates were quite similar for the indicated compounds. Of note, the variations
between replicates were slightly higher in 384WP, with an average SD that was approximately 4%
higher in 384WP than in 96WP. Taken together, we conclude that the optimized platform performed in
384WP is as reliable as the 96WP-based model and it can be used to screen novel anti-biofilms.
2.7. Screening Campaign Against S. aureus Biofilms in 384WP
The optimized 384WP platform was next used to screen a library containing 2000 compounds
against S. aureus biofilms, both for the capacity to prevent biofilm formation (pre-exposure mode) and
to destroy pre-formed biofilms (post-exposure mode) (Figure 9). As in the pilot screen, the compounds
were tested at 10 µM and biofilms were grown and analyzed, as described above. We set-up
empiric thresholds to categorize the screening results. Compounds displaying an inhibition of at
least 80% were regarded as highly active, while compounds with an inhibitory activity of at least
60% were considered to be moderately active. The identity of the compounds and the screening
results are available as supplementary material (Table S2). Overall, 77 compounds were able to
prevent biofilm formation by at least 80% (according to both the resazurin and crystal violet staining).
A list of all these hits and their inhibitory activity is provided (Table A1, Appendix A). However,
no compound significantly affected pre-formed biofilms, which is not surprising when considering the
high chemotolerance of biofilms. Of the 77 positive hits initially identified in pre-exposure, 50 were
known antibacterial compounds and seven were known to be anti-infective, which suggests that the
screening platform worked well in identifying compounds with previously recognized antibacterial
activity. Five other hits were known antifungal compounds: econazole nitrate, amphotericin B,
sulconazole nitrate, miconazole nitrate, and phenylmercuric acetate. For some of those, antibacterial
activity has already been reported [43,44], but no prior studies have been done on the antibacterial
activity of phenylmercuric acetate or sulconazole, at least to be best of our knowledge. It is interesting
to note that amphotericin B is generally thought to be inactive on bacteria, arguably either because
of the drug’s sterol-based mechanism of action or because of the target’s membrane structure [45].
Seven additional hits were neoplastic compounds: teniposide, dactinomycin, mitomycin C, floxuridine,
celastrol, agelasine, and carmofur. The antibacterial activity of those compounds has been investigated
before and some of them seem to hold potential for treatment of bacterial infections, but their high
cytotoxicity generally prevents their use as antibiotics [46–51]. Two of the remaining initial hits are
anti-helminthic drugs. The first, pyrvinium pamoate, has also been identified in a screening against
methicillin-resistant Staphylococcus aureus (MRSA) [52]. The second, niclosamide, has been repeatedly
identified in screening campaigns and investigated for its many potential new purposes, including
as an antibacterial drug [51,53–55]. The five remaining hits, triamcinolone acetonide, chlorthalidone,
physostigmine salicylate, chlorgiline hydrochloride, and chlorpheniramine maleate, were known for
diverse functions that were unrelated to antimicrobial treatment. However, after performing new
follow-up studies on re-purchased compounds, their antibacterial activity could not be confirmed,
and these hits were not pursued any further.
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Figure 9. Results of the screening of a compound library of 2000 compounds tested at 10 µM against
S. aureus biofilms grown in 384WP. (a): prevention of biofilm formation (pre-exposure). (b): destruction
of 18h-old pre-formed biofilms (post-exposure). The effect of the compounds on the biofilms was
assessed by resazurin (x axis) and crystal violet (y axis) staining. The red lines represent the inhibition
thresholds used to select active compounds. Results are expressed as inhibition percentages of viability
or biomass in comparison to untreated biofilms and they are based on two independent biological
replica experiments.
3. Materials and Methods
3.1. Bacterial Growth and Biofilm Formation
The biofilm-producing strains of S. aureus ATCC 25,923 (Faculty of Pharmacy, University
of Helsinki, Helsinki, Fi land) and P. aeruginosa ATCC 15,442 (provided by the Laborator f
Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antw rpen, Belgium)
were seeded on tryptic soy agar (TSA) (LAB011, Lab M Ltd., Heywood, United Kingdo )
and grown vernight under aerobic conditions at 37 ◦C. The bacteria were then suspended
in 5 mL of tryptic soy broth (TSB) (LAB004, Lab M Ltd.) a d grown to exponential phase
under aerobic conditions at 37 ◦C with shaking (220 rpm) until the cells reached approximately
4.00 × 108 CFU (Colony Forming Unit) mL−1 for S. aureus and 1. 109 CFU mL−1 for P. aeruginosa.
The biofilms were formed in polystyrene 384WP (NuncTM 242757, Thermo Fisher Scientific,
Roskilde, Denmark) or 96WP (NuncTM 161093, Thermo Fisher Scientific, Roskilde, De mark) from
various dilutions (for S. aureus: 4.00 × 106 CFU mL−1, 2.50 × 106 CFU mL−1, 7.00 × 105 CFU mL−1,
7.00 × 104 CFU mL−1, and 7.00 × 103 CFU mL−1; for P. aeruginosa: 1.00 × 107 CFU mL−1,
6.25 × 106 CFU mL−1, 1.75 ×106 CFU mL−1, 1.75 ×105 CFU mL−1, and 1.75 × 104 CFU mL−1) of the
initial bacterial suspension. For each species, the plates were incubated for 18 h or 42 h under aerobic
conditions at 37 ◦C, 220 rpm. For the 42 h-old biofilms, the media was changed after 18 h of incubation.
3.2. Resazurin Staining
The resazurin staining was performed, as described earlier [15], with some modifications. Briefly,
the planktonic solution was discarded very gently, attempting to minimize any disruptions to the
biofilms. The biofilms were washed once with a worki g volume (e ther 40 µL or 50 µL in 384WP or
200 µL in 96WP) of ph sphate buffered saline (PBS) (BR0014, Thermo Fisher Scientific, Basingstoke,
England). The washed biofilm cells were inc bated with different concentrations of re azurin (20, 40
60, 80, 100, and 200 µM) in the darkness at room temperature (RT) or a 37 ◦C (when i dicated), with
agitation (2 rpm) for various periods of time (S. aureu : 5, 10, 20, 30, and 40 min; P. aeruginosa: 5, 10,
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20, 30, 40, 60, and 80 min.). The resazurin sodium salt (R7017, Sigma–Aldrich, St. Louis, MO, USA)
was dissolved in PBS to obtain a stock solution of 400 µM (or 0.1 mg mL−1), which was subsequently
diluted in PBS to achieve the indicated concentrations for staining the biofilm cells. Fluorescence was
measured at λexcitation = 560 nm and λemission = 590 nm while using the top optics of the Varioskan
LUX Multimode microplate reader (Thermo Scientific, Vantaa, Finland). After the measurement, the
resazurin solution was removed from the wells, and the biofilms were stained with crystal violet,
as follows.
3.3. Crystal Violet Staining
After resazurin staining, biofilms were subsequently stained with crystal violet as previously
reported [14]. To fix the biofilms, a working volume of ethanol 100% (either 40 µL or 50 µL in 384WP
or 200 µL in 96WP) was added onto the biofilms and the 96WP/384WP plates were incubated at RT.
After 15 min. the lids were removed, and wells were allowed to air-dry completely. The biofilms
were stained with various concentrations (0.023%, 0.1%, 0.23%, 1% v/v) of crystal violet (HT90132,
Sigma-Aldrich, St. Louis, MO, USA) at RT for five minutes and then washed twice with deionized H2O
and left to dry a few minutes (5 min. for 96WP, up to 10 min. for 384WP). The crystal violet bound to
the biofilms was solubilized in 96% ethanol for 1 h at RT. The absorbance was measured at 595 nm
with a Multiskan Sky microplate spectrophotometer (Thermo Scientific, Vantaa, Finland).
3.4. Comparing the CFUs of Biofilms formed in 384WP and 96WP
The biofilms of S. aureus and P. aeruginosa were grown in both 96WP and 384WP, as described
previously. The bacteria were seeded in the wells at a concentration of 4.00× 106 CFU mL−1 (S. aureus) or
1.00× 107 CFU mL−1 (P. aeruginosa) in 96WP and 7.00× 104 CFU mL−1 (S. aureus) or 1.75 × 105 CFU mL−1
(P. aeruginosa) in 384WP. The concentration of the bacterial cells selected for 384WP was based on
the obtained results during the optimization steps. After 18 h or 42 h, the planktonic bacteria were
discarded, and biofilms were washed once with a working volume of PBS. The biofilms were then
scraped using a pipette tip in either 20 µL (384WP) or 100 µL (96WP) of PBS and clumps were
thoroughly broken by repeated pipetting. The bacteria were serially diluted in PBS and 10 µL drops of
the dilutions (10−4 to 10−7) were spotted on TSA to measure the formation of viable colonies.
3.5. Comparing the Antibiotic Susceptibility of S. aureus Biofilms in 384WP and 96WP
A small panel of four well-characterized antibiotics (penicillin, rifampicin, oxacillin,
and doxycycline; Sigma–Aldrich, St. Louis, MO, USA), with diverse chemotypes and three different
mechanisms of action, were tested against S. aureus (Scheme 1). For that purpose, the antibiotics
were dissolved in dimethyl sulfoxide (DMSO) (34943, Sigma–Aldrich, St. Louis, MO, USA) to obtain
a stock solution of 20 mM. The tested antibiotics were further dissolved in DMSO is such a way
that the final concentration of DMSO did not exceed 2.5% (v/v). A pre-exposure mode was used in
which the antibiotics (1 µL per well in 384WP and 5 µL per well in 96WP) were added into the wells
at the same time with the bacterial suspensions. The following parameters were used: (i) the total
working volume for 384WP was 40 µL and 200 µL for 96WP, (ii) for 384WP the added concentration
of suspended cells was 7.00 × 104 CFU mL−1, whereas a higher concentration of added suspended
cells (4.00 × 106 CFU mL−1) was used for 96WP. The inhibition capacity of the indicated antibiotics at
different concentrations was measured after 18 h whlie using the resazurin (20 µM, 30 min.) and crystal
violet assays, as described above.
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antibiotics using the pre-exposure mode in 96WP and 384WP.
3.6. Pilot Screening Against S. aureus Biofilms in 384WP and 96WP
A total of 100 compounds were tested on S. aureus biofilms grown in 96WP and 384WP
platforms. Eighty-eight of them were from a natural derivatives collection (NDL-3000, TimTec Inc.,
Newark, DE, USA), two were provided by the medicinal chemistry group (Division of Pharmaceutical
Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland), and were
synthesized, as described in [56]. The remaining 10 were well-known antibiotics, included for control
purposes. All of the compounds were dissolved in DMSO:PBS (1:1, v/v) to a concentration of 400 µM.
One µL per well (384WP) or 5 µL per well (96WP) of compound (at a final concentration of 10 µM) were
added to the test plates in a final working volume of 40 µL in 384WP and 200µl in 96WP. The screening
was performed using the pre-exposure (antibiotics added at the same time as the bacteria, cells with
compounds cultured for 18 h) and post-exposure (antibiotics added onto 18 h-old biofilms, cells with
compounds incubated for 24 h) modes. The S. aureus inoculum concentration was 7.00 × 104 CFU mL−1
in 384WP and 4.00 × 106 CFU mL−1 in 96WP. The effect of the compounds was assessed while using the
resazurin (20 µM in pre-exposure and 40 µM in post-exposure, 30 min. incubation at RT in darkness,
220 rpm) and crystal violet (0.023%, v/v), 5 min. incubation, 1 h dissolution in EtOH at RT) staining
assays, as described above. The list of all tested compounds, sources, and their screening results in
96WP and 384WP is available in the Supplementary Table S1.
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3.7. Screening of a Compound Library against S. aureus
The commercially available Microsource Spectrum Collection (Discovery Systems Inc.,
Gaylordsville, CT, USA) was screened on S. aureus biofilms that were grown in 384WP.
The 2000 compounds were received as dry powders and solubilized in DMSO:PBS (1:1, v/v) to
a concentration of 200 µM. Two µL per well of compound were added to the test plates in a
final working volume of 40 µL (for a final concentration of 10 µM). As for the pilot screening,
the screening was performed while using the pre-exposure and post-exposure modes and the S. aureus
inoculum concentration was 7.00 × 104 CFU mL−1. The wells were treated, as described in Section 2.6,
using the resazurin and crystal violet staining assays to measure the effect on biofilms viability.
The list of all tested compounds, sources and their screening results in 384WP is available in the
Supplementary Materials (Table S2).
3.8. Statistical Analysis
The inhibition results of bacterial growth by antibiotics are shown as the percent of
control ± S.D. (standard deviation). The assay performance was monitored using the screening window
coefficient Z’ factor (Z’, Equation (1)) and the signal-to-noise (S/N, Equation (2)), calculated with the
following equations, according to [36,57], respectively:
Z’ = (1 − (3 × s.d.max + 3 × s.d.min))/(Xmax − Xmin) (1)
S/N = (Xmax − Xmin)/√(s.d.max2 − s.d.min2) (2)
Xmin and s.d.min are the average and the standard deviation of the readings that were obtained in
media controls (wells containing only sterile TSB) and Xmax and s.d.max are the average and standard
deviation of the readings obtained in biofilm controls (wells containing untreated bacteria).
4. Conclusions
In this work, we have miniaturized an antibacterial screening platform combining the resazurin
and crystal violet staining into 384WP format while using two different bacterial species, S. aureus and
P. aeruginosa, as gram-positive and gram-negative biofilm-forming models, respectively. The method
was optimized in terms of initial bacterial cell concentrations, working volumes, the resazurin and
crystal violet concentrations, and incubation times. Despite a slightly higher well-to-well variability
detected in 384WP when compared to 96WP, we show that the miniaturized platform produces high
quality results and that the resazurin staining and crystal violet staining can be easily applied to 384WP
to study changes in bacterial biofilm formation. Through antibacterial challenges and a validatory
small-scale pilot screen, we also showed that the obtained results are comparable to those obtained
in 96WP, making this miniaturized platform suitable for the large-scale screening of antimicrobial
compounds. A screening of 2000 compounds using this platform further confirmed its applicability.
Although no new compounds worth taking further as a lead candidate were identified, interesting
observations were made on many compounds that are not presently used as antibiotics, and our results
were confirmative of earlier findings that were made during other screening studies. Other parameters,
including the shaking speed during the incubation, which can affect biofilm formation and tolerance,
were not studied here. The effect of the smaller working volume and the shape of the wells in the
384WP on the distribution of nutrients and oxygen and, thereby, the overall architecture of the biofilms,
also remains to be studied. Nevertheless, our screening campaign, by indicating many previously
identified compounds, strengthens the applicability of the optimized 384 platform in the reliable
identification of new antibacterial compounds. In addition, this platform was shown to allow the
testing of four-times the number of compounds in a single run as compared to 96WP with less amount
of materials needed. In conclusion, the optimized 384WP platform demonstrates that resazurin and
crystal violet can be applied for high-throughput anti-biofilm screening in 384WP.
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ATCC American Type Culture Collection
CFU Colony-forming unit
DMSO Dimethyl sulfoxide
HTS High-throughput screening
MDPI Multidisciplinary Digital Publishing Institute
MIC Minimum inhibitory concentration
MoA Mode of action
OD Optical density
PBS Phosphate buffered saline
Rpm Revolutions per minute
RT Room temperature
S.D. Standard deviation
S/N Signal-to-noise
TSA Tryptic soy agar
TSB Tryptic soy broth
96WP 96-well plate
384WP 384-well plate
Z’ Z’ factor
Appendix A
Table A1. Hits preventing over 80% of S. aureus biofilm formation from the screening of 2000 compounds
from the Microsource Spectrum Collection (Discovery Systems Inc.).
Compound Name
% Inhibition Biofilm Formation
Main Known Function 1
Viability Biomass
CETYLPYRIDINIUM CHLORIDE 99 95 anti-infective
MINOCYCLINE HYDROCHLORIDE 95 92 antibacterial
ECONAZOLE NITRATE 94 92 antifungal
NOVOBIOCIN SODIUM 99 90 antibacterial
MECLOCYCLINE SULFOSALICYLATE 97 93 antibacterial
TENIPOSIDE 97 91 antineoplastic
AZLOCILLIN SODIUM 99 92 antibacterial
AMPHOTERICIN B 95 94 antifungal
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Table A1. Cont.
Compound Name
% Inhibition Biofilm Formation
Main Known Function 1
Viability Biomass
LOMEFLOXACIN HYDROCHLORIDE 85 86 antibacterial
CEFAMANDOLE SODIUM 99 94 antibacterial
NAFCILLIN SODIUM 99 92 antibacterial
DACTINOMYCIN 101 96 antineoplastic
DIRITHROMYCIN 100 94 antibacterial
MITOMYCIN C 83 85 antineoplastic
RIFAXIMIN 98 88 antibacterial
CHLORHEXIDINE 82 86 antibacterial, disinfectant
NORFLOXACIN 99 94 antibacterial
OFLOXACIN 95 95 antibacterial
METHACYCLINE HYDROCHLORIDE 99 94 antibacterial
BENZETHONIUM CHLORIDE 101 95 anti-infective
CEPHALOTHIN SODIUM 99 88 antibacterial
SULCONAZOLE NITRATE 95 92 antifungal
GEMIFLOXACIN MESYLATE 97 93 antibacterial
THIMEROSAL 98 91 anti-infective,preservative
PENICILLIN G POTASSIUM 96 92 antibacterial
RIFAMPIN 101 95 antibacterial
TRIAMCINOLONE ACETONIDE 90 90 anti-inflammatory
HETACILLIN POTASSIUM 99 80 antibacterial
CHLORPHENIRAMINE (S) MALEATE 80 84 antihistaminic
PENICILLIN V POTASSIUM 98 88 antibacterial
CLINDAMYCIN HYDROCHLORIDE 99 97 antibacterial
HEXACHLOROPHENE 95 89 anti-infective
GENTIAN VIOLET 100 92 antibacterial,anti-helminthic
PYRVINIUM PAMOATE 99 94 anti-helminthic
MICONAZOLE NITRATE 88 90 antifungal
CHLORTETRACYCLINE
HYDROCHLORIDE 96 89 antibacterial, anti-amebic
DICLOXACILLIN SODIUM 101 96 antibacterial
LINCOMYCIN HYDROCHLORIDE 92 89 antibacterial
CHLORTHALIDONE 98 86 diuretic,antihypertensive
PHYSOSTIGMINE SALICYLATE 99 86 cholinergic, miotic
CLOXACILLIN SODIUM 97 87 antibacterial
PHENYLMERCURIC ACETATE 99 95 antifungal
ERYTHROMYCIN ETHYLSUCCINATE 99 92 antibacterial
FURAZOLIDONE 97 94 antibacterial
TRIMETHOPRIM 85 85 antibacterial
FUSIDIC ACID 95 92 antibacterial
VANCOMYCIN HYDROCHLORIDE 95 96 antibacterial
PHENETHICILLIN POTASSIUM 100 85 antibacterial
ROXITHROMYCIN 99 94 antibacterial
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Table A1. Cont.
Compound Name
% Inhibition Biofilm Formation
Main Known Function 1
Viability Biomass
MOXIFLOXACIN HYDROCHLORIDE 90 84 antibacterial
CEFTIBUTEN 100 93 antibacterial
BACAMPICILLIN HYDROCHLORIDE 100 98 antibacterial
TYLOSIN TARTRATE 99 96 antibacterial
RETINYL PALMITATE 100 95 provitamin
FLOXURIDINE 100 86 antineoplastic
CEFDINIR 101 98 antibacterial
SARAFLOXACIN HYDROCHLORIDE 93 84 antibacterial
TRICLOSAN 101 94 anti-infective
TELITHROMYCIN 100 88 antibacterial
NICLOSAMIDE 87 81 anthelmintic, teniacide
LEVOFLOXACIN 97 89 antibacterial
CIPROFLOXACIN 97 93 antibacterial, fungicide
TICARCILLIN DISODIUM 101 100 antibacterial
TILMICOSIN 101 101 antibacterial
GATIFLOXACIN 93 99 antibacterial
METHYLBENZETHONIUM CHLORIDE 99 91 anti-infective
AZITHROMYCIN 100 97 antibacterial
MUPIROCIN 100 97 antibacterial
PEFLOXACINE MESYLATE 99 95 antibacterial
TEICOPLANIN 99 94 antibacterial
ERYTHROMYCIN STEARATE 97 93 antibacterial
CETRIMONIUM BROMIDE 95 90 anti-infective
CLORGILINE HYDROCHLORIDE 99 87 antidepressant
CELASTROL 100 96 antineoplastic
FLORFENICOL 97 85 antibacterial
AGELASINE 100 96 antineoplastic
CARMOFUR 90 89 antineoplastic
1 Provided by Discovery Systems Inc.
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